Holen Sie sich die Stockscreener-App
1.04
0.97%
0.01
Handel nachbörslich:
1.03
-0.01
-0.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTSO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.03
Offen:
$1.02
24-Stunden-Volumen:
23,627
Relative Volume:
0.21
Marktkapitalisierung:
$65.11M
Einnahmen:
$33.79M
Nettoeinkommen (Verlust:
$-18.67M
KGV:
-2.9034
EPS:
-0.3582
Netto-Cashflow:
$-19.17M
1W Leistung:
-0.95%
1M Leistung:
-11.86%
6M Leistung:
+0.00%
1J Leistung:
-0.95%
1-Tages-Spanne:
$1.01
$1.05
1-Wochen-Bereich:
$0.99
$1.10
52-Wochen-Spanne:
$0.7101
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Firmenname
Cytosorbents Corp
Sektor
Branche
Telefon
973-329-8885
Adresse
305 COLLEGE ROAD EAST, PRINCETON, NJ
Vergleichen Sie CTSO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
1.04 | 65.74M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-07 | Eingeleitet | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2020-09-17 | Eingeleitet | Jefferies | Buy |
| 2020-09-01 | Eingeleitet | SVB Leerink | Outperform |
| 2017-08-08 | Bestätigt | Maxim Group | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-05-24 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | Bestätigt | MLV & Co | Buy |
| 2015-04-01 | Bestätigt | MLV & Co | Buy |
| 2015-03-05 | Eingeleitet | MLV & Co | Buy |
| 2015-02-25 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-01-27 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Cytosorbents Corp Aktie (CTSO) Neueste Nachrichten
What analysts say about Cytosorbents Corporation stockExceptional risk-adjusted gains - jammulinksnews.com
Is Cytosorbents Corporation a good long term investmentExtraordinary profit generation - jammulinksnews.com
What drives Cytosorbents Corporation stock priceMassive wealth growth - jammulinksnews.com
What institutions are buying Cytosorbents Corporation stock nowLong Term Low Risk Growth - Newser
Why Cytosorbents Corporation stock attracts strong analyst attentionFree Access to Stock Community - Newser
What makes Cytosorbents Corporation stock price move sharplyRisk Controlled Trading Ideas - Newser
Cytosorbents stock plunges after regulatory setbacks for key device - Investing.com
CytoSorbents provides FDA, Health Canada regulatory update for DrugSorb-ATR - TipRanks
Cytosorbents Provides U.S. FDA And Health Canada Regulatory Update For Drugsorb-Atr - TradingView
CytoSorbents receives FDA appeal hearing date for DrugSorb-ATR device - Investing.com
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR - PR Newswire
Cytosorbents Corporation(NasdaqCM: CTSO) added to Russell Microcap Index - MarketScreener
Cytosorbents (NASDAQ:CTSO) Given “Buy” Rating at D. Boral Capital - Defense World
CytoSorbents files appeal with FDA over denied device application - Investing.com
CytoSorbents Q1 2025 slides: Revenue dips 3% as company targets breakeven by year-end - Investing.com
Millennium Management LLC Buys Shares of 33,280 Cytosorbents Co. (NASDAQ:CTSO) - Defense World
Cytosorbents announces voting results from annual meeting By Investing.com - Investing.com Canada
Cytosorbents announces voting results from annual meeting - Investing.com
CytoSorbents Warrants Expire Worthless as Stock Price Fails Threshold - Investing.com
Cytosorbents Co. (NASDAQ:CTSO) Shares Purchased by Northern Trust Corp - Defense World
Critical Care Leader CytoSorbents Reveals Growth Strategy at Jefferies Healthcare Conference - Stock Titan
Cytosorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented At EuroPCR 2025 - marketscreener.com
CytoSorbents device cuts bleeding in CABG patients - Investing.com
New Clinical Data: How CytoSorbents' Breakthrough Device Slashes Severe Bleeding Risk in Urgent Heart Surgery - Stock Titan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - Defense World
Cytosorbents FY2025 EPS Forecast Lifted by HC Wainwright - Defense World
D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Earns Neutral Rating from HC Wainwright - Defense World
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents Corp’s Earnings Call: A Balanced Outlook - TipRanks
CytoSorbents (CTSO) Receives Neutral Rating from HC Wainwright & Co. | CTSO Stock News - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | CTSO Stock News - GuruFocus
CytoSorbents: Q1 Earnings Snapshot - CT Insider
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and Strengthening Financials - GuruFocus
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents (CTSO) Targets Growth Amid Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents Q1 2025 misses earnings, stock dips - Investing.com
CytoSorbents Corp Q1 2025 Earnings: EPS of -$0.06 Beats Estimate, Revenue of $8.7M Misses Estimate - GuruFocus
CTSO Reports Q1 Revenue Below Expectations Amid Strategic Changes in Germany | CTSO Stock News - GuruFocus
CytoSorbents Corporation Q1 2025 Financial Results - TradingView
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Finanzdaten der Cytosorbents Corp-Aktie (CTSO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):